{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:51:41Z","timestamp":1774615901144,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-12412-1","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T10:38:27Z","timestamp":1771497507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rifapentine-isoniazid versus isoniazid-alone therapy for tuberculosis prevention among people living with HIV (PLHIV): a systematic review and meta-analysis of randomized trials"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3575-5764","authenticated-orcid":false,"given":"Syed Hassan","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Shayaan","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila Tul","family":"Qadar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Selsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Duharte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moustafa","family":"Hegazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afsana Ansari","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Sohaib","family":"Asghar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"issue":"1","key":"12412_CR1","first-page":"58","volume":"18","author":"R Bansal","year":"2018","unstructured":"Bansal R, Sharma D, Singh R. Tuberculosis and its treatment: an overview. Mini Rev Med Chem. 2018;18(1):58\u201371.","journal-title":"Mini Rev Med Chem"},{"key":"12412_CR2","unstructured":"Global tuberculosis. report 2024 [Internet]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240101531. [cited 16 Jan 2025]."},{"key":"12412_CR3","unstructured":"Identification of populations for testing and treatment of latent tuberculosis infection. In: latent tuberculosis infection: updated and consolidated guidelines for programmatic management [Internet]. World Health Organization. 2018. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK531231\/. [cited 16 Jan 2025]."},{"issue":"1","key":"12412_CR4","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1186\/s12879-023-08575-4","volume":"23","author":"CC Qi","year":"2023","unstructured":"Qi CC, Xu LR, Zhao CJ, Zhang HY, Li QY, Liu MJ, et al. Prevalence and risk factors of tuberculosis among people living with HIV\/AIDS in china: a systematic review and meta-analysis. BMC Infect Dis. 2023;23(1):584.","journal-title":"BMC Infect Dis"},{"issue":"10181","key":"12412_CR5","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/S0140-6736(19)30308-3","volume":"393","author":"J Furin","year":"2019","unstructured":"Furin J, Cox H, Pai M, Tuberculosis. Lancet Lond Engl. 2019;393(10181):1642\u201356.","journal-title":"Lancet Lond Engl"},{"key":"12412_CR6","unstructured":"Sk AT. K. Tuberculosis preventive treatment. Indian J Pediatr. [Internet]. 2024;91(8). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38095783\/.\u00a0[cited\u00a0 19 Jan 2025]."},{"key":"12412_CR7","unstructured":"CDCTB, Tuberculosis. (TB) - Treatment regimens for latent TB infection [Internet]. Centers for disease control and prevention. 2022. Available from: https:\/\/www.cdc.gov\/tb\/topic\/treatment\/ltbi.htm.\u00a0[cited 19 Jan 2025]."},{"issue":"1","key":"12412_CR8","doi-asserted-by":"publisher","first-page":"e1003502","DOI":"10.1371\/journal.pmed.1003502","volume":"18","author":"K Dorjee","year":"2021","unstructured":"Dorjee K, Topgyal S, Tsewang T, Tsundue T, Namdon T, Bonomo E, et al. Risk of developing active tuberculosis following tuberculosis screening and preventive therapy for Tibetan refugee children and adolescents in india: an impact assessment. PLoS Med. 2021;18(1):e1003502.","journal-title":"PLoS Med"},{"key":"12412_CR9","doi-asserted-by":"crossref","unstructured":"Huang H, Yuan G, Du Y, Cai X, Liu J, Hu C, et al. Effects of preventive therapy for latent tuberculosis infection and factors associated with treatment abandonment: a cross-sectional study. J Thorac Dis [Internet]. 2018;10(7). Available from: https:\/\/jtd.amegroups.org\/article\/view\/22518.\u00a0[cited 19 Jan 2025].","DOI":"10.21037\/jtd.2018.06.138"},{"key":"12412_CR10","unstructured":"Organization WH. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management [Internet]. World Health Organization; 2018. Available from: https:\/\/iris.who.int\/handle\/10665\/260233.\u00a0[cited 19 Jan 2025]."},{"issue":"2","key":"12412_CR11","doi-asserted-by":"publisher","first-page":"e20172838","DOI":"10.1542\/peds.2017-2838","volume":"141","author":"AT Cruz","year":"2018","unstructured":"Cruz AT, Starke JR. Completion rate and safety of tuberculosis infection treatment with shorter regimens. Pediatrics. 2018;141(2):e20172838.","journal-title":"Pediatrics"},{"key":"12412_CR12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.11604\/pamj.2024.48.86.43117","volume":"48","author":"RM Malaka","year":"2024","unstructured":"Malaka RM, Cele L, Mogale M, Simbeni T. Completion rate of tuberculosis preventive therapy and incidence of tuberculosis among people living with the human immunodeficiency virus on antiretroviral therapy in Ekurhuleni East subdistrict, Gauteng Province. Pan Afr Med J. 2024;48:86.","journal-title":"Pan Afr Med J"},{"key":"12412_CR13","doi-asserted-by":"crossref","unstructured":"Lin SY, Wang PH, Feng JY, Shu CC. Higher adverse drug reactions but better completion rate of twelve-dose weekly rifapentine plus isoniazid comparing with nine-month daily isoniazid for latent tuberculosis infection among patients under maintenance dialysis. Eur Respir J [Internet]. 2020;56(64). Available from: https:\/\/publications.ersnet.org\/content\/erj\/56\/suppl_64\/4595.\u00a0[cited 19 Jan 2025].","DOI":"10.1183\/13993003.congress-2020.4595"},{"issue":"9","key":"12412_CR14","doi-asserted-by":"publisher","first-page":"e1003738","DOI":"10.1371\/journal.pmed.1003738","volume":"18","author":"M Yanes-Lane","year":"2021","unstructured":"Yanes-Lane M, Ortiz-Brizuela E, Campbell JR, Benedetti A, Churchyard G, Oxlade O, et al. Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis. PLoS Med. 2021;18(9):e1003738.","journal-title":"PLoS Med"},{"key":"12412_CR15","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;n71.","DOI":"10.1136\/bmj.n71"},{"key":"12412_CR16","unstructured":"RoB 2. a revised tool for assessing risk of bias in randomised trials | The BMJ [Internet]. Available from: https:\/\/www.bmj.com\/content\/366\/bmj.l4898.\u00a0[cited 22 Dec 2024]."},{"issue":"1","key":"12412_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1005136","volume":"365","author":"NA Martinson","year":"2011","unstructured":"Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365(1):11\u201320.","journal-title":"N Engl J Med"},{"issue":"10","key":"12412_CR18","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","volume":"30","author":"TR Sterling","year":"2016","unstructured":"Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, et al. Three months of weekly rifapentine and Isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS Lond Engl. 2016;30(10):1607\u201315.","journal-title":"AIDS Lond Engl"},{"issue":"11","key":"12412_CR19","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","volume":"380","author":"S Swindells","year":"2019","unstructured":"Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One month of rifapentine plus Isoniazid to prevent HIV-Related tuberculosis. N Engl J Med. 2019;380(11):1001\u201311.","journal-title":"N Engl J Med"},{"issue":"10","key":"12412_CR20","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.7326\/M20-7577","volume":"174","author":"G Churchyard","year":"2021","unstructured":"Churchyard G, C\u00e1rdenas V, Chihota V, Mngadi K, Sebe M, Brumskine W, et al. Annual tuberculosis preventive therapy for persons with HIV infection: A randomized trial. Ann Intern Med. 2021;174(10):1367\u201376.","journal-title":"Ann Intern Med"},{"issue":"2","key":"12412_CR21","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.amepre.2018.04.030","volume":"55","author":"GJ Njie","year":"2018","unstructured":"Njie GJ, Morris SB, Woodruff RY, Moro RN, Vernon AA, Borisov AS. Isoniazid-Rifapentine for latent tuberculosis infection: A systematic review and Meta-analysis. Am J Prev Med. 2018;55(2):244\u201352.","journal-title":"Am J Prev Med"},{"issue":"1","key":"12412_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12879-017-2377-x","volume":"17","author":"C Pease","year":"2017","unstructured":"Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P, et al. Efficacy and completion rates of rifapentine and Isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis. 2017;17(1):265.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"12412_CR23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M17-0609","volume":"167","author":"D Zenner","year":"2017","unstructured":"Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of latent tuberculosis infection: an updated network Meta-analysis. Ann Intern Med. 2017;167(4):248\u201355.","journal-title":"Ann Intern Med"},{"issue":"1","key":"12412_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1753-5174.2009.00017.x","volume":"2","author":"C Schmitt","year":"2009","unstructured":"Schmitt C, Riek M, Winters K, Schutz M, Grange S. Unexpected hepatotoxicity of Rifampin and Saquinavir\/Ritonavir in healthy male volunteers. Arch Drug Inf. 2009;2(1):8\u201316.","journal-title":"Arch Drug Inf"},{"issue":"10","key":"12412_CR25","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1128\/AAC.01749-09","volume":"54","author":"V Sekar","year":"2010","unstructured":"Sekar V, Lavreys L, Van de Casteele T, Berckmans C, Spinosa-Guzman S, Vangeneugden T, et al. Pharmacokinetics of darunavir\/ritonavir and Rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother. 2010;54(10):4440\u20135.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12412-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12412-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12412-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:57:49Z","timestamp":1774612669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-12412-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12412"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12412-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study uses publicly available data and hence does not require ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"644"}}